scholarly journals Blue Rubber Bleb Nevus Syndrome: A Possible Cause for Growth Retardation and Pubertal Delay

2018 ◽  
Vol 28 (3) ◽  
pp. 294-296
Author(s):  
Yi Pan ◽  
Lu Zhang ◽  
Minghui Duan ◽  
Hong Yang ◽  
Duoduo Zhao ◽  
...  
Keyword(s):  
Differential Diagnosis ◽  
Iron Deficiency ◽  
Growth Retardation ◽  
Rare Case ◽  
Clinical Presentation ◽  
Intravenous Iron ◽  
Deficiency Anemia ◽  
Pubertal Delay ◽  
Intravenous Iron Therapy ◽  
Possible Cause

Objective: The aim of this paper was to describe a rare case of blue rubber bleb nevus (BRBNS) with growth retardation and pubertal delay. Clinical Presentation and Intervention: A 16-year-old boy with severe iron deficiency anemia was diagnosed with BRBNS, showing growth retardation and pubertal delay simultaneously. The patient was treated conservatively with intravenous iron therapy, and his puberty advanced gradually. Conclusion: Given that growth retardation and pubertal delay are rare in BRBNS patients, this case reminds us to include BRBNS in the differential diagnosis of growth retardation.

scholarly journals Oral versus intravenous iron therapy in iron deficiency anemia: An observational study

2020 ◽  
Vol 9 (7) ◽  
pp. 3619
Author(s):  
PravatK Thatoi ◽  
SamarendraN Das ◽  
Amruta Devi ◽  
BibhutiB Mohanta ◽  
Anurag Choudhury ◽  
...  
Keyword(s):  
Iron Deficiency ◽  
Observational Study ◽  
Iron Deficiency Anemia ◽  
Intravenous Iron ◽  
Iron Therapy ◽  
Deficiency Anemia ◽  
Intravenous Iron Therapy

scholarly journals Safety and Efficacy of Intravenous Iron Therapy in Postnatal Patients with Iron Deficiency Anemia

2011 ◽  
Vol 3 (1) ◽  
pp. 25-27 ◽  
Author(s):  
Shahnaz Kouser ◽  
Shaheen Kouser ◽  
Mariam Malik ◽  
Ahmad Malik
Keyword(s):  
Iron Deficiency ◽  
Prospective Study ◽  
Iron Deficiency Anemia ◽  
Intravenous Iron ◽  
Iron Therapy ◽  
Deficiency Anemia ◽  
Allergic Reactions ◽  
Safety And Efficacy ◽  
Moderate Anemia ◽  
Intravenous Iron Therapy

ABSTRACT Objective This prospective study was conducted to establish safety and efficacy of intravenous iron therapy in postnatal anemic patients. Results Around 217 anemic women were included in the study. Most of these patients (82.2%) were of 21 to 30 years of age having parity of 2 to 4 (53.9%). Almost 71% of patients had moderate anemia with Hb of 7 to 9 gm/dl. Around 208 patients (95.86%) required two to four injections of intravenous iron to build up Hb to optimum acceptable level. Only seven patients (3.22%) suffered from minor complications of local rash, while three (1.38%) had more severe allergic reactions but were managed successfully. Conclusion Intravenous iron is a safe and effective alternative in postnatal patients as it ensures iron therapy in low resource and noncompliant patients.

Intravenous Iron Therapy: A Summary of Treatment Options and Review of Guidelines

2008 ◽  
Vol 21 (6) ◽  
pp. 431-443 ◽  
Author(s):  
Scott B. Silverstein ◽  
Jeffrey A. Gilreath ◽  
George M. Rodgers
Keyword(s):  
Molecular Weight ◽  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Intravenous Iron ◽  
Oral Iron ◽  
Iron Therapy ◽  
Deficiency Anemia ◽  
Iron Dextran ◽  
Functional Iron Deficiency ◽  
Intravenous Iron Therapy

Iron replacement for iron-deficiency anemia has historically been accomplished with the use of oral iron therapy. Although oral iron is appropriate for most iron-deficiency anemia patients, many patients do not respond to or may be intolerant of oral iron, or may experience bleeding of sufficient magnitude to require higher iron doses than that achievable with oral iron. Intravenous iron therapy is a useful option for these latter patients. Three intravenous iron products are recommended: low-molecular weight iron dextran (INFeD), ferric gluconate (Ferrlecit), and iron sucrose (Venofer). These intravenous iron products have superior safety profiles compared to high-molecular weight iron dextran. The Food and Drug Administration's approval of erythropoietic-stimulating agents to treat certain types of anemia has increased usage of intravenous iron for functional iron deficiency. This review summarizes the current status of intravenous iron products and discusses their advantages and disadvantages in treating both absolute and functional iron deficiency.

scholarly journals Iron Deficiency Anemia-Induced Lymphocytopenia in a Young Female

2020 ◽  
Vol 13 (2) ◽  
pp. 793-797
Author(s):  
Elabbass A. Abdelmahmuod ◽  
Mohamed A. Yassin
Keyword(s):  
Iron Deficiency ◽  
Blood Loss ◽  
Iron Deficiency Anemia ◽  
Uterine Fibroids ◽  
Intravenous Iron ◽  
Young Female ◽  
Food Sources ◽  
Deficiency Anemia ◽  
Intravenous Iron Therapy ◽  
Poor Absorption

Iron deficiency anemia is the most common type of anemia, and it occurs when the human body does not have enough of the mineral iron (https://www.healthline.com/health/iron-deficiency-anemia#diagnosis). Iron deficiency anemia is caused by blood loss, insufficient dietary intake, or poor absorption of iron from food. Sources of blood loss can include heavy periods, childbirth, uterine fibroids, stomach ulcers, colon cancer, and urinary tract bleeding (https://www.nhlbi.nih.gov/health-topics/iron-deficiency-anemia). Poor absorption of iron from food may occur as a result of an intestinal disorder such as inflammatory bowel disease or celiac disease, or surgery such as a gastric bypass (https://www.who.int/nutrition/topics/ida/en/). Little is known about the association between iron deficiency anemia and lymphocytopenia. Here, we report on a 17-year-old female who presented with iron deficiency anemia and was found to have lymphopenia. She recovered after having received intravenous iron therapy.

Sign in / Sign up

Export Citation Format

Share Document